Atkore Buyout: $3.8B Prysmian Deal at $95/Share
Atkore surges 26.4% premarket on a $3.8 billion cash takeover by Prysmian at $95 per share. Here's the arb setup and what traders need to know now.
Key Points
- Prysmian has agreed to acquire Atkore in an all-cash deal at $95 per share, valuing the transaction at $3.8 billion — Atkore shares are up 26.4% in premarket trading to reflect the offer price.
- The all-cash structure eliminates equity consideration risk, making this a clean merger arbitrage setup where the spread between current trading price and $95 represents the market's implied probability of deal closure and timing.
- Traders should monitor the spread compression rate against the deal timeline and any regulatory filings — Prysmian is an Italian-listed infrastructure and cable conglomerate, meaning antitrust review in both the U.S. and EU is the primary deal-break risk.
Prysmian will pay $95 per share in cash for Atkore, the Chicago-based electrical conduit and cable management manufacturer, in a $3.8 billion definitive agreement announced Monday morning — sending ATKR up 26.4% in premarket trading. For merger arbitrage traders, the structure is clean: all cash, no stock component, no financing contingency language in the initial release. The spread between where ATKR opens and $95 is pure deal risk, and the only question worth asking is how long this takes to close and what could kill it.
The Deal Structure and Arb Setup
All-cash buyouts are the simplest merger arb setups in the market. There is no acquirer stock to hedge, no exchange ratio to recalculate, and no equity market exposure on the consideration side. Prysmian is paying $95 per share, full stop. If ATKR opens at, say, $92-$93 — consistent with a 26% jump from Friday's close of approximately $73-$74, back-calculating from the premarket move — the spread to $95 represents roughly 200-300 basis points of annualized return on a deal that most industrial M&A transactions suggest will close in six to nine months. That is a competitive return against the 4.68% 10-year Treasury, and a substantially better risk-adjusted outcome than most carry trades in today's rate environment, provided the deal closes.
The $3.8 billion price tag puts this squarely in the territory where U.S. antitrust review under the Hart-Scott-Rodino Act is mandatory, and Prysmian's European headquarters adds an EU merger review dimension. Prysmian is the world's largest cable manufacturer by revenue, with significant market share in power and telecom cables across North America and Europe. Atkore operates in electrical raceway products — conduit, cable trays, and fittings — which are adjacent to but not identical to Prysmian's core cable manufacturing business. The overlap question for regulators will center on whether the combined entity achieves dominant positioning in the U.S. electrical infrastructure supply chain at a moment when grid modernization spending is accelerating. That is a non-trivial regulatory question, and it is the primary deal-break risk arb traders need to handicap.
Why Prysmian Wants Atkore
The strategic logic is not hard to reconstruct. U.S. infrastructure investment — driven by the residual tail of the 2021 infrastructure law and ongoing data center and grid buildout capex — has created durable demand for exactly the products Atkore makes. Electrical conduit and cable management systems are not glamorous, but they are embedded in every commercial construction project, every data center rack row, and every utility substation upgrade. Prysmian, which already supplies the wire and cable that goes inside Atkore's conduit systems, is essentially buying the last-mile distribution and raceway infrastructure that its own products depend on. Vertical integration at this level is a classic industrial consolidation play, and at a moment when U.S. manufacturing capacity is being reshored aggressively, owning both the cable and the conduit puts Prysmian in a formidable negotiating position with large EPC contractors.
Atkore's financials had been under pressure heading into this deal. The company had faced a post-pandemic normalization in PVC resin prices — a key input cost — and volume headwinds as the housing cycle cooled from its 2021-2022 peak. Friday's close near $73-$74 was well below the stock's 52-week high, suggesting Prysmian timed the acquisition during a period of ATKR multiple compression. At $3.8 billion, the purchase price likely represents a 10-12x EBITDA multiple on Atkore's normalized earnings — in line with recent industrials M&A comps but not a blowout premium that would suggest Prysmian overpaid. The market reaction to ATKR — up 26.4% — versus any reaction in Prysmian's Milan-listed shares will be worth tracking when European markets update, as acquirer discount dynamics are as relevant in cross-border deals as in domestic ones.
Spread Mechanics and What Traders Watch Next
The mechanics of trading the spread from here depend on two variables: your entry price relative to $95, and your timeline assumption for regulatory clearance. If ATKR opens at $92, you are buying a $3 spread — approximately 3.3% gross return. Annualized over a nine-month close, that is roughly 4.4%, slightly below the 10-year yield but with a different risk profile than duration. The real money in merger arb is made when the market misprices deal-break probability — either by pricing in too much risk on a deal likely to close, or too little on a deal with genuine antitrust exposure. Today, the early read is that antitrust risk is moderate but not prohibitive: the product overlap between Prysmian and Atkore is real but unlikely to trigger a full block absent very aggressive regulatory posture.
The AstraZeneca-Bristol Myers Squibb situation reported this morning — a deal reportedly involving $400 billion in enterprise value — is a useful contrast. AZN fell 5.9% in premarket trading on overpay concerns, which is the classic acquirer discount signal on a mega-deal. The Prysmian-Atkore deal is orders of magnitude smaller, the strategic rationale is tighter, and there is no currency risk given the all-cash structure. For the short-side of that AZN trade, the $400 billion figure — if accurate — would represent one of the largest pharmaceutical combinations in history, dwarfing even the $74 billion AbbVie-Allergan transaction from 2019. The market's immediate negative reaction to AZN suggests institutional investors are reading it as value-destructive at that price. Monitoring whether AZN's premarket decline holds through the open will indicate whether a short thesis develops legs.
Back to ATKR: the specific dates traders need on their calendars are the HSR filing deadline — typically within 30 days of deal announcement — and any EU Phase 1 review clock, which runs 25 working days from notification. If Prysmian files promptly and regulators take no extended action, a Q1 2027 close is achievable. Any second request from the DOJ, or a Phase 2 referral in Europe, extends the timeline by three to six months and compresses the annualized arb return materially. Watch for the proxy statement and merger agreement filing with the SEC — likely within 20 business days — for the precise termination fee, financing representations, and regulatory covenant language. Those three clauses will tell you everything you need to know about how confident Prysmian's legal team is in a clean close. The $95 ceiling holds until it doesn't — and in this rate environment, every basis point of spread has a buyer.
The Weekly Investor
Daily market analysis for active traders. Free.
